

29 May 2020

Tender results

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender, dated 1 November 2019.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of June 2020 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023

CORRECTION to February 2020 tender notification

PHARMAC incorrectly notified a Sole Subsidised Supply Status award in February 2020 for gemcitabine hydrochloride injection in Section B (community) when this should have been an award for Hospital Supply Status in Part II of Section H (Hospital Medicines List). Correction in strikethrough and bold below:

~~Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule~~

~~1. Tenders awarded to pharmaceuticals where at least one other brand is listed.~~

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Gemcitabine hydrochloride	Inj 10 mg per ml, 100 ml vial; 1 vial pack	\$15.89	\$15.89	Gemcitabine Ebewe (Novartis)	1 April 2020	1 July 2020	Eli Lilly (Gemzar)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Gemcitabine	Inj 10 mg per ml, 100 ml vial; 1 vial pack	\$15.89	\$15.89	Gemcitabine Ebewe (Novartis)	1%	1 April 2020	1 July 2020

CORRECTION to April 2020 tender notification:

PHARMAC incorrectly notified the dates relating to the bisoprolol fumarate tablet tender awards. Corrections are in **bold** and strikethrough below.

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Bisoprolol fumarate ¹	Tab 2.5 mg; 90 tablet blister pack	\$3.53	\$1.84	Bisoprolol Mylan (Mylan)	1 September 2020 1 November 2020	1 February 2021 1 April 2021	Bosvate (Douglas)
Bisoprolol fumarate ¹	Tab 5 mg; 90 tablet bottle pack	\$5.15	\$2.55	Bisoprolol Mylan (Mylan)	1 September 2020 1 November 2020	1 February 2021 1 April 2021	Bosvate (Douglas)
Bisoprolol fumarate ¹	Tab 10 mg; 90 tablet blister pack	\$9.40	\$3.62	Bisoprolol Mylan (Mylan)	1 September 2020 1 November 2020	1 February 2021 1 April 2021	Bosvate (Douglas)

¹ Brand switch fee of \$4.50 is payable for this product from ~~1 February 2021~~ 1 April 2021 to ~~30 April 2021~~ 30 June 2021

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Bisoprolol fumarate	Tab 2.5 mg; 90 tablet blister pack	\$3.53	\$1.84	Bisoprolol Mylan (Mylan)	1 September 2020 1 November 2020	1 February 2021 1 April 2021	Bosvate (Douglas)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Bisoprolol fumarate	Tab 5 mg; 90 tablet bottle pack	\$5.15	\$2.55	Bisoprolol Mylan (Mylan)	1 September 2020 1 November 2020	1 February 2021 1 April 2021	Bosvate (Douglas)
Bisoprolol fumarate	Tab 10 mg; 90 tablet blister pack	\$9.40	\$3.62	Bisoprolol Mylan (Mylan)	1 September 2020 1 November 2020	1 February 2021 1 April 2021	Bosvate (Douglas)

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

May 2020 tender notification

1. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows (changes in bold):

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Amoxicillin with clavulanic acid	Tab 500 mg with clavulanic acid 125 mg; 10 tablet blister pack	\$1.88 (20 tablet pack)	\$0.89	Curam Duo 500/125 (Novartis New Zealand Limited)	1 February 2021	1 July 2021	Augmentin (GSK)
Anastrozole	Tab 1 mg; 30 tablet blister pack	\$5.04	\$4.55	Anatrole (Mylan)	1 November 2020	1 April 2021	Rolin (Rex Medical)
Calcium carbonate	Tab 1.25 g (500 mg elemental); 250 tablet bottle pack	\$7.52	\$6.69	Calci-Tab 500 (AFT)	1 December 2020	1 May 2021	Arrow-Calcium (Teva)
Emulsifying ointment	Oint BP: 500 g tub	\$3.59	\$3.40	Emulsifying Ointment ADE (ADE Health Ltd)	1 October 2020	1 March 2021	AFT (AFT)
Hydroxyurea [Hydroxycarbamide] ²	Cap 500 mg; 100 capsule box pack	\$31.76	\$23.82	Devatis (Deva Holdings (NZ) Ltd)	1 September 2020	1 February 2021	Hydrea (Bristol-Myers Squibb (NZ) Limited)

² Brand switch fee of \$4.50 is payable for this product from 1 February 2021 to 30 April 2021

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows (changes in bold):

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Amoxicillin with clavulanic acid	Tab 500 mg with clavulanic acid 125 mg; 10 tablet blister pack	\$1.88 (20 tablet pack)	\$0.89	Curam Duo 500/125 (Novartis New Zealand Limited)	1%	1 February 2021	1 July 2021	Augmentin (GSK)
Anastrozole	Tab 1 mg; 30 tablet blister pack	\$5.04	\$4.55	Anatrole (Mylan)	1%	1 November 2020	1 April 2021	Rolin (Rex Medical)
Calcium carbonate	Tab 1.25 g (500 mg elemental); 250 tablet bottle pack	\$7.52	\$6.69	Calci-Tab 500 (AFT)	1%	1 December 2020	1 May 2021	Arrow-Calcium (Teva)
Emulsifying ointment	Oint BP: 500 g tub	\$3.59	\$3.40	Emulsifying Ointment ADE (ADE Health)	1%	1 October 2020	1 March 2021	AFT (AFT)
Hydroxyurea [Hydroxycarbamide]	Cap 500 mg; 100 capsule box pack	\$31.76	\$23.82	Devatis (Deva Holdings (NZ) Ltd)	1%	1 September 2020	1 February 2021	Hydrea (Bristol-Myers Squibb (NZ) Limited)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

- the 2017/18 Invitation to Tender, dated 2 November 2017, and
- the 2018/19 Invitation to Tender, dated 1 November 2018, and
- the 2019/20 Invitation to Tender, dated 1 November 2019.

2017/18 Invitation to Tender

Chemical name	Line item
Amoxicillin clavulanate	Grans for oral liq amoxicillin 400 mg with potassium clavulanate 57 mg per 5 ml
Chlorhexidine gluconate	Mouthwash 0.2%
Diclofenac sodium	Eye drops 0.1%
Methotrexate	Inj 7.5 mg prefilled syringe
Methotrexate	Inj 10 mg prefilled syringe
Methotrexate	Inj 15 mg prefilled syringe
Methotrexate	Inj 20 mg prefilled syringe
Methotrexate	Inj 25 mg prefilled syringe
Methotrexate	Inj 30 mg prefilled syringe
Midodrine	Tab 2.5 mg
Midodrine	Tab 5 mg
Mitozantrone	Inj 2 mg per ml, 10 ml
Oxycodone hydrochloride	Oral liq 1 mg per ml

2018/19 Invitation to Tender

Chemical name	Line item
Captopril	Oral liq 5 mg per ml

2019/20 Invitation to Tender

Chemical name	Line item
Amikacin	Inj 15 mg per ml
Amiloride with Hydrochlorothiazide	Tab 5 mg with hydrochlorothiazide 50 mg
Aminophylline	Inj 25 mg per ml, 10 ml
Amoxicillin	Inj 1 g
Amoxicillin	Inj 250 mg
Amoxicillin	Inj 500 mg
Baclofen	Inj 0.05 mg per ml, 1 ml
Betaxolol hydrochloride	Eye drops 0.25%
Betaxolol hydrochloride	Eye drops 0.5%
Bupivacaine hydrochloride	Inj 1.25 mg per ml, 100 ml bag
Bupivacaine hydrochloride	Inj 2.5 mg per ml, 200 ml bag
Bupivacaine hydrochloride	Inj 1.25 mg per ml, 500ml bag
Bupivacaine hydrochloride	Inj 5 mg per ml, 20 ml ampoule
Captopril	Oral liq 5 mg per ml
Cefotaxime	Inj 500 mg
Chlorhexidine gluconate	Soln 4%
Chlorhexidine gluconate	Crm 1% obstetric
Chlorhexidine gluconate	Lotn 1% obstetric

Chemical name	Line item
Chloroquine phosphate	Tab 250 mg
Cimetidine	Tab 200 mg
Cimetidine	Tab 400 mg
Clarithromycin	Tab 250 mg
Clarithromycin	Tab 500 mg
Danazol	Cap 100 mg
Danazol	Cap 200 mg
Desmopressin	Nasal drops 100 mcg per ml
Desmopressin	Inj 4 mcg per ml, 1 ml
Desmopressin	Tab 200 mcg
Desmopressin	Inj 15 mcg per ml, 1 ml
Dextrochlorpheniramine Maleate	Oral liq 2 mg per 5 ml
Dinoprostone	Gel 1 mg
Dinoprostone	Gel 2 mg
Doxycycline	Tab 20 mg - 50 mg
Doxycycline	Inj 100 mg per 20 ml
Ethinylloestradiol with Desogestrel	Tab 20 mcg with desogestrel 150 mcg
Ethinylloestradiol with Desogestrel	Tab 30 mcg with desogestrel 150 mcg

Chemical name	Line item
Ethinylestradiol with levonorgestrel	Tab 50 mcg with levonorgestrel 125 mcg
Flucloxacillin sodium	Inj 250 mg
Flucloxacillin sodium	Inj 500 mg
Flucloxacillin Sodium	Inj 2 g
Flucytosine	Cap 500 mg
Glucose [Dextrose]	Tab 3.1 g
Glucose [Dextrose]	Tab 4 g
Glucose [Dextrose]	Tab 1.5 g
Glucose with sucrose and fructose	Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet
Imipramine Hydrochloride	Tab 10 mg
Imipramine Hydrochloride	Tab 25 mg
Imiquimod	Crm 5%
Lidocaine [Lignocaine]	Crm 4%
Lithium carbonate	Cap (immediate-release) 250 mg
Lithium Carbonate	Tab (immediate-release) 250 mg
Lithium Carbonate	Tab long-acting 400 mg
Medroxyprogesterone acetate	Tab 100 mg
Medroxyprogesterone acetate	Tab 2.5 mg
Medroxyprogesterone acetate	Tab 5 mg
Medroxyprogesterone acetate	Tab 10 mg

Chemical name	Line item
Melatonin	Tab modified-release 2 mg
Menthol	Crystals
Metoclopramide hydrochloride	Oral liq 5 mg per 5 ml
Mifepristone	Tab 200 mg
Nicardipine hydrochloride	Inj 2.5 mg per ml, 10 ml vial
Nitazoxanide	Oral 100 mg per 5 ml
Nitazoxanide	Tab 500 mg
Noradrenaline	Inj 0.06 mg per ml, 100 ml bag
Noradrenaline	Inj 0.12 mg per ml, 50 ml syringe
Noradrenaline	Inj 1 mg per ml, 100 ml bag
Noradrenaline	Inj 0.16 mg per ml, 50 ml vial
Noradrenaline	Inj 0.16 mg per ml, 100 ml bag
Oestrogens	Conjugated, equine tab 300 mcg
Oestrogens	Conjugated, equine tab 625 mcg
Paracetamol	Tab 500 mg, blister pack
Paracetamol	Tab 500 mg, bottle pack
Paraffin liquid with soft white paraffin	Eye oint with soft white paraffin
Paraffin liquid with wool fat liquid	Eye oint 3% with wool fat liq 3%
Paraldehyde	Inj 5 ml
Perindopril	Tab 2 mg - 2.5 mg

Chemical name	Line item
Perindopril	Tab 4 mg – 5 mg
Perindopril	Tab 8 mg – 10 mg
Phenelzine sulphate	Tab 15 mg
Pravastatin	Tab 10 mg
Procaine penicillin	Inj 1.5 mega u
Protonamide	Tab 250 mg
Quinine dihydrochloride	Inj 600 mg
Rasagiline	Tab 1 mg
Rifabutin	Cap 150 mg
Sodium cromoglicate	Nasal spray, 4%
Tramadol hydrochloride	Inj 10 mg per ml, 100 ml bag

Chemical name	Line item
Tranlycypromine Sulphate	Tab 10 mg
Triamcinolone acetonide	Inj 10 mg per ml, 1 ml preservative-free
Wool fat with mineral oil	Lotn hydrous 3% with mineral oil, 250 ml
Xylometazoline hydrochloride	Nasal drops 0.1%
Xylometazoline hydrochloride	Aqueous nasal spray 0.05%
Xylometazoline hydrochloride	Aqueous nasal spray 0.1%
Xylometazoline hydrochloride	Nasal drops 0.05%
Zuclopenthixol Acetate	Inj 50 mg per ml, 1 - 2 ml
Zuclopenthixol Decanoate	Inj 200 mg per ml
Zuclopenthixol decanoate	Inj 500 mg per ml

For products included in the 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.